Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular Carcinoma: Analysis of REACH Trial Results by Child-Pugh Score.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

REACH is the first phase 3 trial to provide information on hepatocellular cancer (HCC) in the second-line (postsorafenib) setting categorized by Child-Pugh score, a scoring system used to measure the severity of chronic liver disease. This exploratory analysis demonstrates the relationship between a potential ramucirumab survival benefit, severity of liver disease, and baseline α-fetoprotein (αFP).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): JAMA Oncol

Title: JAMA oncology

Publisher: American Medical Association (AMA)

ISSN (Electronic): 2374-2445

ISSN (Print): 2374-2437

Publication date (Electronic): Sep 22 2016

Affiliations

[1 ] Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston.

[2 ] California Pacific Medical Center, San Francisco.

[3 ] Otto von Guericke University of Magdeburg, Magdeburg, Germany.

[4 ] Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.

[5 ] Saga-Ken Medical Centre Koseikan, Saga, Japan.

[6 ] Surgery Department CHU Estaing, Clermond Ferrand, France.

[7 ] Evangelisches Krankenhaus Bielefeld, Bielefeld, Germany.

[8 ] Policlinico Sant' Orsola-Malpighi, Bologna, Italy.

[9 ] Catholic University of Sacred Heart, Rome, Italy.

[10 ] Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.

[11 ] National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.

[12 ] Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

[13 ] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

[14 ] Gangnam Severance Hospital, Seoul, South Korea.

[15 ] Yonsei Cancer Center, Cancer Metastasis Research Center, Yonsei University College of Medicine, Shinchon-Dong, South Korea.

[16 ] Division of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan17National Yang-Ming University School of Medicine, Taipei, Taiwan.

[17 ] National Cheng Kung University Hospital, Tainan City, Taiwan.

[18 ] Chang Gung Memorial Hospital, Chiayi, Taiwan.

[19 ] Eli Lilly and Company, Bridgewater, New Jersey.

[20 ] AstraZeneca Pharmaceuticals, Wilmington, Delaware.

[21 ] Eli Lilly and Company, Indianapolis, Indiana.

[22 ] Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.

Article

Publisher Item ID: 2553753

DOI: 10.1001/jamaoncol.2016.4115

PubMed ID: 27657674

SO-VID: 220eae88-91c9-40e3-b290-59eb2edae508

History

Data availability:

Comments

Comment on this article

scite_

Cited by 37

See all cited by

- Version 1